LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

MRK

109.68

+0.27%↑

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

MRK

109.68

+0.27%↑

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

MRK

109.68

+0.27%↑

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

MRK

109.68

+0.27%↑

LLY

931.66

+2.23%↑

UNH

597.99

+0.06%↑

JNJ

161.35

+0.45%↑

ABBV

194.33

-0.02%↓

MRK

109.68

+0.27%↑

Inicio・Lista de Acciones・Novo Nordisk A-S

Novo Nordisk A-S

Cerrado

Sector Salud

119.89 2.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

117.53

Máximo

120.55

Métricas clave
By Trading Economics
Ingresos	-5.4B 20B
Ventas	2.7B 68B
P/B Media del Sector	49.94 113.916
BPA	4.49
Margen de beneficio	29.459
EBITDA	-1.2B 36B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+32.09 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-6.4B 394B
Apertura anterior	117.86
Cierre anterior	119.89

Noticias sobre sentimiento de mercado

By Acuity

27%

73%

110 / 366 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

117.49 / 120.76 Soporte y Resistencia

Novo Nordisk A-S Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 sept 2024, 19:26 UTC

Principales Movimientos del Mercado

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

4 oct 2024, 12:01 UTC

Principales Noticias

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 oct 2024, 12:01 UTC

Principales Noticias

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

3 oct 2024, 14:45 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 13:12 UTC

Principales Noticias

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct 2024, 12:51 UTC

Charlas de Mercado

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2 oct 2024, 13:48 UTC

Ganancias

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2 oct 2024, 12:28 UTC

Charlas de Mercado

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2 oct 2024, 09:00 UTC

Charlas de Mercado

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

26 sept 2024, 13:15 UTC

Charlas de Mercado

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

26 sept 2024, 11:51 UTC

Charlas de Mercado

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

23 sept 2024, 10:37 UTC

Principales Noticias

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

23 sept 2024, 10:37 UTC

Principales Noticias

Fed Uncertainty Is History. Now Markets Need to -2-

20 sept 2024, 16:30 UTC

Charlas de Mercado

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

20 sept 2024, 13:55 UTC

Principales Noticias

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20 sept 2024, 12:46 UTC

Principales Noticias

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20 sept 2024, 09:30 UTC

Principales Noticias

The Price War in Weight-Loss Drugs Is Here -- WSJ

12 sept 2024, 13:00 UTC

Principales Noticias

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12 sept 2024, 11:45 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12 sept 2024, 10:30 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11 sept 2024, 12:08 UTC

Principales Noticias

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9 sept 2024, 07:56 UTC

Charlas de Mercado

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 sept 2024, 11:09 UTC

Principales Noticias

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 ago 2024, 05:30 UTC

Principales Noticias

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 ago 2024, 12:01 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 ago 2024, 11:30 UTC

Principales Noticias

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 ago 2024, 07:30 UTC

Charlas de Mercado

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 ago 2024, 15:44 UTC

Principales Noticias

Ganancias

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

8 ago 2024, 11:36 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Share-Price Weakness Provides an Opportunity -- Market Talk

8 ago 2024, 07:16 UTC

Charlas de Mercado

Ganancias

Novo Nordisk's Share-Price Drop Provides Buying Opportunity -- Market Talk

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S Esperado

Precio Objetivo

By TipRanks

32.09% repunte

Estimación a 12 meses

Media 155.25 USD 32.09%

Máximo 160 USD

Mínimo 146 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Novo Nordisk A-S Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

117.49 / 120.76Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

110 / 366 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.